胶质瘤组织学与分子改变与胼胝体侵犯的关联
该研究纳入331例胶质瘤患者(86例侵犯胼胝体),分析临床病理特征及四种常规分子标志物;另选29对患者行68个胶质瘤分子改变的深度测序。多因素分析显示WHO分级是胼胝体侵犯的危险因素(p=0.001),PDGFRA突变在侵犯组9例(31%)而对照组仅1例(3.4%)(OR 17.331;95% CI 1.987-151.156)。
要点
- WHO分级是胶质瘤侵犯胼胝体的独立危险因素(p=0.001)。
- PDGFRA突变与胼胝体侵犯显著相关(OR 17.331;95% CI 1.987-151.156)。
- 侵犯胼胝体的胶质瘤在遗传表达谱上呈现独特生物学实体特征。
核心结论
- 胶质瘤侵犯胼胝体可能与WHO分级和PDGFRA突变相关,而非其他因素。
- 侵犯胼胝体的胶质瘤在遗传表达谱上表现为独特的生物学实体。
研究设计与样本
- 第一部分纳入331例胶质瘤患者,其中86例(26%)诊断为侵犯性胶质瘤,分析基本临床病理特征及四种常规检测的胶质瘤分子标志物。
- 第二部分从两组中各选取29对患者,对68个胶质瘤分子改变进行深度测序分析。
主要发现
- 单因素分析显示两组在基本因素上无差异,多因素logistic分析显示WHO分级是胼胝体侵犯的危险因素(p=0.001)。
- 配对组具有不同的遗传表达谱,提示侵犯胼胝体的胶质瘤为独特生物学实体。
- PDGFRA突变在侵犯性胶质瘤患者中9例(31%),对照组仅1例(3.4%)(OR 17.331;95% CI 1.987-151.156)。
关键数值与推荐
- 胼胝体侵犯在331例胶质瘤患者中占86例(26%)。
- WHO分级与胼胝体侵犯的多因素logistic分析p=0.001。
- PDGFRA突变与胼胝体侵犯的OR为17.331(95% CI 1.987-151.156)。
临床怎么用
- 对胶质瘤患者评估WHO分级和PDGFRA突变状态可能有助于识别胼胝体侵犯高风险者。
- PDGFRA相关风险信号通路可能为该类疾病提供潜在治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioma invading the corpus callosum (CC) accounts for approximately 14% of gliomas and is thought to be more aggressive. However, there is still a lack of studies on the pathogenesis and molecular features of this condition. Here, we examined the occurrence association of CC invasion with respect to patients' clinical, pathological, and genetic characteristics. METHODS: First, a cohort of 331 patients was included, with 86 cases (26%) that were diagnosed with invasion glioma. They were all analyzed for basic clinical and pathological characteristics and four routinely tested glioma molecular markers. Second, 29 pairs of patients who underwent deep sequencing of 68 glioma molecular alterations were selected from both groups for in-depth analysis. RESULTS: The results of the first part showed that there was no difference between the two groups in terms of the basic factors in univariate analysis, while in multivariate logistic analysis, WHO grade was the risk factor for CC invasion (p = 0.001). The results of the second part showed that the paired groups had different genetic expression profiles, which highlighted glioma invading the CC as a distinct biological entity. PDGFRA mutation (PDGFRAmut) was present in 9 patients with invasive gliomas (31%), but only in one case (3.4%) in the control group (OR 17.331; 95% CI 1.987-151.156). CONCLUSION: Our data revealed the clinical, pathological, and genetic characteristics of glioma invading the CC and showed that it may be associated with glioma WHO grade and PDGFRAmut, but not other factors. Thus, the risk signaling pathway may offer potential therapeutic targets for this disease.
引用
- Shen S, Feng S, Liu H, et al. Associations of histological and molecular alterations with invasion of the corpus callosum in gliomas. Acta Neurochir (Wien). 2020. PMID: 32440925. doi:10.1007/s00701-020-04376-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。